Expanded Access Program for olaparib tablets as maintenance therapy in patients with ovarian, fallopian tube or primary peritoneal cancer.

Trial Identifier:	D0816R00014
Sponsor:	AstraZeneca
Collaborator:	PAREXEL
NCTID::	NCT03079687
Condition:	Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States of America, CA	Newport Beach, CA, United States of America, 92663

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.